Estrogen Receptor beta antibody [7B10.7]
GTX70182
ApplicationsImmunoPrecipitation, Western Blot, ChIP Chromatin ImmunoPrecipitation
Product group Antibodies
ReactivityHuman
TargetESR2
Overview
- SupplierGeneTex
- Product NameEstrogen Receptor beta antibody [7B10.7]
- Delivery Days Customer9
- Application Supplier NoteWB: 1 - 5 microg/ml. *Optimal dilutions/concentrations should be determined by the researcher.Not tested in other applications.
- ApplicationsImmunoPrecipitation, Western Blot, ChIP Chromatin ImmunoPrecipitation
- CertificationResearch Use Only
- ClonalityMonoclonal
- Clone ID7B10.7
- Concentration1 mg/ml
- ConjugateUnconjugated
- Gene ID2100
- Target nameESR2
- Target descriptionestrogen receptor 2
- Target synonymsER-BETA, ESR-BETA, ESRB, ESTRB, Erb, NR3A2, ODG8, estrogen receptor beta, estrogen receptor beta 2, estrogen receptor beta 4, nuclear receptor subfamily 3 group A member 2, oestrogen receptor beta
- HostMouse
- IsotypeIgG1
- Protein IDQ92731
- Protein NameEstrogen receptor beta
- Scientific DescriptionThis gene encodes a member of the family of estrogen receptors and superfamily of nuclear receptor transcription factors. The gene product contains an N-terminal DNA binding domain and C-terminal ligand binding domain and is localized to the nucleus, cytoplasm, and mitochondria. Upon binding to 17beta-estradiol or related ligands, the encoded protein forms homo- or hetero-dimers that interact with specific DNA sequences to activate transcription. Some isoforms dominantly inhibit the activity of other estrogen receptor family members. Several alternatively spliced transcript variants of this gene have been described, but the full-length nature of some of these variants has not been fully characterized. [provided by RefSeq, Jul 2008]
- ReactivityHuman
- Storage Instruction-20°C or -80°C,2°C to 8°C
- UNSPSC12352203
References
- Sellitto A, D'Agostino Y, Alexandrova E, et al. Insights into the Role of Estrogen Receptor β in Triple-Negative Breast Cancer. Cancers (Basel). 2020,12(6). doi: 10.3390/cancers12061477Read this paper
- Lu W, Katzenellenbogen BS. Estrogen Receptor-β Modulation of the ERα-p53 Loop Regulating Gene Expression, Proliferation, and Apoptosis in Breast Cancer. Horm Cancer. 2017,8(4):230-242. doi: 10.1007/s12672-017-0298-1Read this paper
- Nelson AW, Groen AJ, Miller JL, et al. Comprehensive assessment of estrogen receptor beta antibodies in cancer cell line models and tissue reveals critical limitations in reagent specificity. Mol Cell Endocrinol. 2017,440:138-150. doi: 10.1016/j.mce.2016.11.016Read this paper
- Monsivais D, Dyson MT, Yin P, et al. Estrogen receptor β regulates endometriotic cell survival through serum and glucocorticoid-regulated kinase activation. Fertil Steril. 2016,105(5):1266-1273. doi: 10.1016/j.fertnstert.2016.01.012Read this paper
- Monsivais D, Dyson MT, Yin P, et al. ERβ- and prostaglandin E2-regulated pathways integrate cell proliferation via Ras-like and estrogen-regulated growth inhibitor in endometriosis. Mol Endocrinol. 2014,28(8):1304-15. doi: 10.1210/me.2013-1421Read this paper
- Ruddy SC, Lau R, Cabrita MA, et al. Preferential estrogen receptor β ligands reduce Bcl-2 expression in hormone-resistant breast cancer cells to increase autophagy. Mol Cancer Ther. 2014,13(7):1882-93. doi: 10.1158/1535-7163.MCT-13-1066Read this paper
- Jiang Y, Gong P, Madak-Erdogan Z, et al. Mechanisms enforcing the estrogen receptor β selectivity of botanical estrogens. FASEB J. 2013,27(11):4406-18. doi: 10.1096/fj.13-234617Read this paper
- Madak-Erdogan Z, Charn TH, Jiang Y, et al. Integrative genomics of gene and metabolic regulation by estrogen receptors α and β, and their coregulators. Mol Syst Biol. 2013,9:676. doi: 10.1038/msb.2013.28Read this paper
- Krishnamurthy N, Hu Y, Siedlak S, et al. Induction of quinone reductase by tamoxifen or DPN protects against mammary tumorigenesis. FASEB J. 2012,26(10):3993-4002. doi: 10.1096/fj.12-208330Read this paper
- Paruthiyil S, Cvoro A, Tagliaferri M, et al. Estrogen receptor β causes a G2 cell cycle arrest by inhibiting CDK1 activity through the regulation of cyclin B1, GADD45A, and BTG2. Breast Cancer Res Treat. 2011,129(3):777-84. doi: 10.1007/s10549-010-1273-5Read this paper




